Australia opened Paedneo‑Vax, the world’s first multisite pediatric trial testing individualized mRNA cancer vaccines for aggressive childhood brain tumors. Funded by Providence Therapeutics, the trial will evaluate personalized mRNA constructs tailored to each child’s tumor antigens across multiple Australian sites. The study represents a novel application of individualized mRNA technology in pediatric oncology and combines government and philanthropic support with industry funding to accelerate a highly personalized immunotherapy approach.